Bactericidal Peptides from Avian Leukocyte Ribonuclease A-2

These bactericidal polypeptides offer a novel alternative to conventional antibiotics that are used to treat and prevent bacterial infections. As infection-causing bacteria continue to develop antibiotic resistance to first line antibiotics there will always be a need for new antibiotic alternatives. Additionally, a greater understanding of the specific cytoxic activity of RNase A ribonucleases, their functional domains, and their roles in promoting anti-pathogen host defense may provide insight into new therapeutic agents.

This invention includes a novel RNase A ribonuclease from chicken leukocytes and polypeptides that have bactericidal activities against both gram positive and gram negative bacteria, including such pathogens as Escherichia coli, Salmonella spp., and Staphylococcus.

Potential Commercial Applications: Competitive Advantages:
  • Polypeptides exhibiting bactericidal, bacteriostatic, and ribonuclease activity.
  • Pharmaceutical compositions comprising the bactericidal polypeptides.
  • Methods for treating bacterial infections.

Development Stage:
Early stage


Helene Rosenberg (NIAID)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 8,748,572 issued 2014-06-10
US Application No. 60/840,268
PCT Application No. PCT/US2007/018690
US Application No. 14/297,078

T Nitto, KD Dyer, M Czapiga, HF Rosenberg. Evolution and function of leukocyte RNase A ribonucleases of the avian species, Gallus gallus. J Biol Chem. 2006 Sep 1;281(35):25622-25634. PubMed abs

Collaboration Opportunity:

The NIAID Laboratory of Allergic Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact William Ronnenberg, NIAID Office of Technology Development, at 301-451-3522 or for more information.

Licensing Contact:
Dianca Finch, Ph.D.
Phone: 240-669-5503

OTT Reference No: E-281-2006-0
Updated: Sep 18, 2009